Probiotics for inflammatory bowel diseases: a promising adjuvant treatment

References

• Aureli P, Capurso L, Castellazzi AM, Clerici M, Giovannini M, Morelli L, Poli A, Pregliasco F, Salvini F, Zuccotti GV. 2011. Probiotics and health: an evidence-based review. Pharmacol Res. 63:366–376.
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. 2005. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 100:1539–1546.
   PubMed Web of Science ®Google Scholar
• Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, Marteau P, Rampal P, Moyse D, Saleh A, et al. 2013. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol. 11:982–987.
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, et al. 2005. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 11:833–839.
   PubMed Web of Science ®Google Scholar
• Cain AM, Karpa KD. 2011. Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med. 17:72–79.
   PubMed Web of Science ®Google Scholar
• Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. 2007. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig Dis Sci. 52:385–389.
   PubMed Web of Science ®Google Scholar
• Coqueiro AY, Bonvini A, Raizel R, Tirapegui J, Rogero MM. 2018. Probiotic supplementation in dental caries: is it possible to replace conventional treatment? Nutrire. 43:6.
   Google Scholar
• Coqueiro AY, Bonvini A, Tirapegui J, Rogero MM. 2017. Probiotics Supplementation as an alternative method for celiac disease treatment. Int J Probiot Prebiot. 12:23–32.
   Google Scholar
• Di Cagno R, De Angelis M, De Pasquale I, Ndagijimana M, Vernocchi P, Ricciuti P, Gagliardi F, Laghi L, Crecchio C, Guerzoni ME, et al. 2011. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol. 11:219.
   PubMed Web of Science ®Google Scholar
• FAO and WHO. 2002. Guidelines for the evaluation of probiotics in food. Food and Agriculture Organization of the United Nations/World Health Organization, London, Ontario. www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
   Google Scholar
• Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, et al. 2015. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol. 13:928–935.
   PubMed Web of Science ®Google Scholar
• Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Bischoff SC. 2017. ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 36:321–347.
   PubMed Web of Science ®Google Scholar
• Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C. 2007. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease. J Gastroenterol Hepatol. 22:1199–1204.
   PubMed Web of Science ®Google Scholar
• Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil DA, Macfarlane GT. 2005. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 54:242–249.
   PubMed Web of Science ®Google Scholar
• Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, Machado JA, Correia MI, Cardoso VN. 2011. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr. 50:261–269.
   PubMed Web of Science ®Google Scholar
• Gersemann M, Wehkamp J, Stange EF. 2012. Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 271:421–428.
   PubMed Web of Science ®Google Scholar
• Guenther K, Straube E, Pfister W, Guenther A, Huebler A. 2010. Sever sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J. 29:188–189.
   PubMed Web of Science ®Google Scholar
• Guindi M, Riddell RH. 2004. Indeterminate colitis. J Clin Pathol. 57:1233–1244.
   PubMed Web of Science ®Google Scholar
• Gupta P, Andrew H, Kirschner BS, Guandalini S. 2000. Is lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 31:453–457.
   PubMed Web of Science ®Google Scholar
• Guslandi M, Giollo P, Testoni PA. 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 15:697–698.
   PubMed Web of Science ®Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. 2000. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 45:1462–1464.
   PubMed Web of Science ®Google Scholar
• Gómez-Llorente C, Muñoz S, Gil A. 2010. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proc Nutr Soc. 69:381–389.
   PubMed Web of Science ®Google Scholar
• Hegazy SK, El-Bedewy MM. 2010. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol. 16:4145–4151.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11:506–514.
   PubMed Web of Science ®Google Scholar
• Imaoka A, Shima T, Kato K, Mizuno S, Uehara T, Matsumoto S, Setoyama H, Hara T, Umesaki Y. 2008. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol. 14:2511–2516.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, Tanaka R, Otani T. 2011. Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 84:128–133.
   PubMed Web of Science ®Google Scholar
• Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 11:853–858.
   PubMed Web of Science ®Google Scholar
• Li G, Zeng S, Liao W, Lv N. 2012. The effect of bifid triple viable on immune function of patients with ulcerative colitis. Gastroenterol Res Pract. 2012:404752.
   PubMedGoogle Scholar
• Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. 2004. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis. 38:1690–1699.
   PubMed Web of Science ®Google Scholar
• Malchow HA. 1997. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol. 25:653–658.
   PubMed Web of Science ®Google Scholar
• Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Bourreille A, Metman E, et al. 2006. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 55:842–847.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M. 2005. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol. 140:417–426.
   PubMed Web of Science ®Google Scholar
• Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. 2010. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 10:13.
   PubMed Web of Science ®Google Scholar
• Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. 2009. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 104:437–443.
   PubMed Web of Science ®Google Scholar
• Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. 2009. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15:300–310.
   PubMed Web of Science ®Google Scholar
• Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G, Buscemi S, Gerges-Geagea A, Jurjus A, Tomasello G. 2016. The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 160:372–377.
   PubMed Web of Science ®Google Scholar
• Peluso I, Fina D, Caruso R, Stolfi C, Caprioli F, Fantini MC, Caspani G, Grossi E, Di Iorio L, Paone FM. 2007. Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. Infect Immun. 75:1730–1737.
   PubMed Web of Science ®Google Scholar
• Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. 2014. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis. 8:1498–1505.
   PubMed Web of Science ®Google Scholar
• Pothoulakis C. 2009. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther. 30:826–833.
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. 2002. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut. 51:405–409.
   PubMed Web of Science ®Google Scholar
• Raizel R, Santini E, Kopper AM, Dos Reis Filho AD. 2011. Effects of probiotics, prebiotics and synbiotics consumption on the human organism. Rev Ciên Saúde. 4:66–74.
   Google Scholar
• Rizzello V, Bonaccorsi I, Dongarrà ML, Fink LN, Ferlazzo G. 2011. Role of natural killer and dendritic cell crosstalk in immunomodulation by commensal bacteria probiotics. J Biomed Biotechnol. 2011:473097.
   PubMedGoogle Scholar
• Santos Rocha C, Lakhdari O, Blottière HM, Blugeon S, Sokol H, Bermúdez-Humarán LG, Azevedo V, Miyoshi A, Doré J, Langella P, et al. 2012. Anti-inflammatory properties of dairy lactobacilli. Inflamm Bowel Dis. 18:657–666.
   PubMed Web of Science ®Google Scholar
• Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. 2004. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 4:5.
   PubMed Web of Science ®Google Scholar
• Scott KP, Antoine JM, Midtvedt T, van Hemert S. 2015. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis. 26:25877
   PubMed Web of Science ®Google Scholar
• Seksik P, Dray X, Sokol H, Marteau P. 2008. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res. 52:906–912.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. 2009. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 7:1202–1209.
   PubMed Web of Science ®Google Scholar
• Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. 2010. Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther. 32:872–883.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, et al. 2016. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc. 28:67–74.
   PubMed Web of Science ®Google Scholar
• Tamboli CP, Neut C, Desreumaux P, Colombel JF. 2004. Dysbiosis in inflammatory bowel disease. Gut. 53:1–4.
   PubMed Web of Science ®Google Scholar
• Tannock GW. 1998. Studies of the intestinal microflora: a prerequisite for the development of probiotics. Int Dairy J. 8:527–533.
   Web of Science ®Google Scholar
• Thomas S, Metzke D, Schmitz J, Dörffel Y, Baumgart DC. 2011. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 301:G1083–G1092.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. 2004. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 10:PI126–PI131.
   PubMed Web of Science ®Google Scholar
• Vanderpool C, Yan F, Polk DB. 2008. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 14:1585–1596.
   PubMed Web of Science ®Google Scholar
• Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. 2011. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 5:115–121.
   PubMed Web of Science ®Google Scholar
• Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, et al. 2006. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 23:1567–1574.
   PubMed Web of Science ®Google Scholar